FGFR2 | ApexOnco - Clinical Trials news and analysis

x

“The team is super responsive to my inquiries and suggestions”

Chief Business Officer

US public biotech company

Click here for more information

Conferences Trial results

13 October 2023

Triple meeting 2023 – Relay shifts to a tumour-agnostic plan

The company’s FGFR2 inhibitor shows potential beyond cholangiocarcinoma, but the markets aren’t buying it.

Subscribe to FGFR2